Form 4: Anika Therapeutics EVP, CFO and Treasurer Stephen D. Griffin Reports Acquisition of Stock Options and Restricted Stock Units

Stephen D. Griffin, EVP, CFO and Treasurer of Anika Therapeutics, reports the acquisition of stock options and restricted stock units.

Summary

• On June 3, 2024, Stephen D. Griffin, the EVP, CFO, and Treasurer of Anika Therapeutics, acquired 96,525 stock options with an exercise price of $29.35, vesting in three equal annual installments beginning June 3, 2025, and expiring on June 3, 2034.
• Griffin also acquired 38,520 restricted stock units (RSUs), each representing the right to receive one share of Anika's common stock, vesting in three equal annual installments beginning June 3, 2025.
• Following these transactions, Griffin directly owns 96,525 stock options and 38,520 RSUs.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options and RSUs to a key executive is generally a positive sign, indicating confidence in the company's future. The vesting schedule aligns the executive's interests with the long-term success of the company.

Positives

• The acquisition of stock options and RSUs by a key executive like the CFO can be seen as a positive sign, indicating confidence in the company's future performance.
• The vesting schedules for both the stock options and RSUs (three equal annual installments beginning June 3, 2025) align the executive's interests with the long-term success of the company.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of the stock options and RSUs suggests a focus on long-term performance.

Industry Context

Executive compensation through stock options and RSUs is a common practice in the biotechnology industry to incentivize performance and align management's interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Zimmer Biomet and Stryker also use stock options and RSUs to incentivize their executives.
• The vesting schedule of three years is also typical in the industry.

Stakeholder Impact

• Shareholders: The acquisition of stock options and RSUs by a key executive can be viewed positively, as it aligns management's interests with the company's long-term success.
• Employees: The executive's increased stake in the company may boost morale and encourage a focus on achieving company goals.

Key Dates